These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 3012320)

  • 1. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties.
    Alvarez R; Banerjee GL; Bruno JJ; Jones GL; Littschwager K; Strosberg AM; Venuti MC
    Mol Pharmacol; 1986 Jun; 29(6):554-60. PubMed ID: 3012320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 7-Bromo-1,5-dihydro-3,6-dimethylimidazo[2,1-b]quinazolin-2(3H)- one (Ro 15-2041), a potent antithrombotic agent that selectively inhibits platelet cyclic AMP-phosphodiesterase.
    Muggli R; Tschopp TB; Mittelholzer E; Baumgartner HR
    J Pharmacol Exp Ther; 1985 Oct; 235(1):212-9. PubMed ID: 2995647
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibitors of cyclic AMP phosphodiesterase. 2. Structural variations of N-cyclohexyl-N-methyl-4-[(1,2,3,5-tetrahydro- 2-oxoimidazo[2,1-b]quinazolin-7-yl)-oxy]butyramide (RS-82856).
    Venuti MC; Jones GH; Alvarez R; Bruno JJ
    J Med Chem; 1987 Feb; 30(2):303-18. PubMed ID: 3027339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacologic and pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 63291 and WIN 62582.
    Pagani ED; Dundore RL; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
    J Cardiovasc Pharmacol; 1994 Sep; 24(3):403-10. PubMed ID: 7528296
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Multiple molecular forms of phosphodiesterase and the regulation of cardiac muscle contractility.
    Weishaar RE; Kobylarz-Singer DC; Quade MM; Steffen RP; Kaplan HR
    J Cyclic Nucleotide Protein Phosphor Res; 1986-1987; 11(7):513-27. PubMed ID: 2831259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation.
    Hidaka H; Hayashi H; Kohri H; Kimura Y; Hosokawa T; Igawa T; Saitoh Y
    J Pharmacol Exp Ther; 1979 Oct; 211(1):26-30. PubMed ID: 226672
    [No Abstract]   [Full Text] [Related]  

  • 7. Functional and biochemical evidence for diazepam as a cyclic nucleotide phosphodiesterase type 4 inhibitor.
    Collado MC; Beleta J; Martinez E; Miralpeix M; Domènech T; Palacios JM; Hernández J
    Br J Pharmacol; 1998 Mar; 123(6):1047-54. PubMed ID: 9559885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro and in vivo inhibitory effects of propentofylline on cyclic AMP phosphodiesterase activity.
    Nagata K; Ogawa T; Omosu M; Fujimoto K; Hayashi S
    Arzneimittelforschung; 1985; 35(7):1034-6. PubMed ID: 2996562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular effects of UK 14,275: evaluation of a new phosphodiesterase inhibitor with inotropic properties in animals and human volunteers [proceedings].
    Follath F; Kersting F; Lewis GR; Dollery CT
    Br J Clin Pharmacol; 1975 Aug; 2(4):372P-373P. PubMed ID: 184804
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostamide and anagrelide.
    Jones GH; Venuti MC; Alvarez R; Bruno JJ; Berks AH; Prince A
    J Med Chem; 1987 Feb; 30(2):295-303. PubMed ID: 3027338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Species-dependent pharmacodynamic effects of the selective low Km cyclic AMP phosphodiesterase III inhibitors WIN 58993 and WIN 62005.
    Dundore RL; Pagani ED; Bode DC; Bacon ER; Singh B; Lesher GY; Buchholz RA; Silver PJ
    J Cardiovasc Pharmacol; 1995 Jan; 25(1):14-21. PubMed ID: 7723343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor Sepharose chromatography.
    Umekawa H; Tanaka T; Kimura Y; Hidaka H
    Biochem Pharmacol; 1984 Nov; 33(21):3339-44. PubMed ID: 6093810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological profile of CR3465, a new leukotriene CysLT1 receptor antagonist with broad anti-inflammatory activity.
    Ferrari F; Mennuni L; Caselli G; Zanelli T; Makovec F
    Eur J Pharmacol; 2004 Nov; 504(3):223-33. PubMed ID: 15541426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cardiovascular responses to a newly developed phosphodiesterase inhibitor, DN-9693 [7-pyperidinyl-1,2,3,5-tetrahydroimidazo (2,1-b)-quinazolin-2-one.HCl] in dog cross-circulated atrial and ventricular preparations.
    Akahane K; Furukawa Y; Haniuda M; Karasawa Y; Chiba S
    Jpn Heart J; 1989 Nov; 30(6):903-15. PubMed ID: 2561162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Two isoforms of cGMP-inhibited cyclic nucleotide phosphodiesterases in human tissues distinguished by their responses to vesnarinone, a new cardiotonic agent.
    Masuoka H; Ito M; Sugioka M; Kozeki H; Konishi T; Tanaka T; Nakano T
    Biochem Biophys Res Commun; 1993 Jan; 190(2):412-7. PubMed ID: 8381275
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyrido and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1-b]quinazoline.
    Venuti MC; Stephenson RA; Alvarez R; Bruno JJ; Strosberg AM
    J Med Chem; 1988 Nov; 31(11):2136-45. PubMed ID: 2846839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differential modulation of cytokine production by drugs: implications for therapy in heart failure.
    Matsumori A; Ono K; Sato Y; Shioi T; Nose Y; Sasayama S
    J Mol Cell Cardiol; 1996 Dec; 28(12):2491-9. PubMed ID: 9004165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. RS-82856, a selective phosphodiesterase inhibitor with inotropic, afterload reduction and antithrombotic properties.
    Strosberg AM; Johnson L; Montgomery W; Lee CH; Alvarez R; Bruno JJ; Jones GH; Venuti MC
    Proc West Pharmacol Soc; 1987; 30():5-10. PubMed ID: 3628319
    [No Abstract]   [Full Text] [Related]  

  • 19. Modulation of rat thymocyte proliferative response through the inhibition of different cyclic nucleotide phosphodiesterase isoforms by means of selective inhibitors and cGMP-elevating agents.
    Marcoz P; Prigent AF; Lagarde M; Nemoz G
    Mol Pharmacol; 1993 Nov; 44(5):1027-35. PubMed ID: 8246905
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro pharmacology of the novel phosphodiesterase type 4 inhibitor, CP-80633.
    Cohan VL; Showell HJ; Fisher DA; Pazoles CJ; Watson JW; Turner CR; Cheng JB
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1356-61. PubMed ID: 8819523
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.